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Abstract
Background: Diagnosing heart failure (HF) in primary care can be challenging, especially in
elderly patients with comorbidities. Insight in the prevalence, age, comorbidity and routine
practice of diagnosing HF in general practice may improve the process of diagnosing HF.
Aim: To examine the prevalence of HF in relation to ageing and comorbidities, and routine
practice of diagnosing HF in general practice. Methods: A retrospective cohort study was
performed using data from electronic health records of 56 320 adult patients of 11 general
practices. HF patients were compared with patients without HF using descriptive analyses
and χ 2 tests. The following comorbidities were considered: chronic obstructive pulmonary
disorder (COPD), diabetes mellitus (DM), hypertension, anaemia and renal function disorder
(RFD). Separate analyses were performed for men and women. Findings: The point
prevalence of HF was 1.2% (95% confidence interval 1.13–1.33) and increased with each age
category from 0.04% (18–44 years) to 20.9% (⩾85 years). All studied comorbidities were
significantly (P< 0.001) more common in HF patients than in patients without HF: COPD
(24.1% versus 3.1%), DM (34.7% versus 6.5%), hypertension (52.7% versus 16.0%), anaemia
(10.9% versus 2.3%) and RFD (61.8% versus 7.5%). N-terminal pro-BNP (NT-proBNP) was
recorded in 38.1% of HF patients. Conclusions: HF is highly associated with ageing and
comorbidities. Diagnostic use of NT-proBNP in routine primary care seems underutilized.
Instruction of GPs to determine NT-proBNP in patients suspected of HF is recommended,
especially In elderly patients with comorbidities.
Introduction
Heart failure (HF) affects an estimated 26 million people worldwide (Ambrosy et al., 2014)
and this number is expected to be increasing due to the ageing population and improved
survival following acute cardiac events (Hobbs et al., 2002; Bleumink et al., 2004). Further-
more, the number of patients with risk factors for HF, in particular obesity and diabetes, is also
increasing. Therefore, the prevalence of HF will probably increase in the near future
(Danielsen et al., 2017). Bleumink et al. (2004) and Hobbs et al. (2002) further appoint that
HF is associated with a significant burden on quality of life, morbidity and mortality, with only
35% of patients surviving five years after diagnosis. Due to the poor prognosis and high
morbidity, it causes high health-care-related costs. In 2011, the estimated costs were 940
million euro in the Netherlands, which was 1.1% of the total healthcare costs. Nearly 50% went
to hospital care and 45% to nursing homes and home care (Rutten et al., 2016).
HF is a complex and progressive syndrome in which the cardiac output is insufficient to
meet the demands of the body due to an abnormality in cardiac structure or function, leading
to a variety of symptoms and signs (Hoes et al., 2010; Yancy et al., 2013; Ponipowski et al.,
2016). HF patients are frequently managed by general practitioners (GPs), which means every
GP will encounter HF patients in their practice (Hoes et al., 1998). Diagnosing HF is difficult,
because many of the symptoms are non-discriminating and, therefore, of limited diagnostic
value (Remes et al., 1991; Mant et al., 2009). Moreover, HF is frequently associated with
comorbidities, hampering clinical assessment. According to the Dutch HF guidelines, the main
(physical) comorbidities associated with HF are chronic obstructive pulmonary disease
(COPD), diabetes mellitus (DM), hypertension, anaemia and renal function disorder (RFD).
These comorbidities may lead to or maintain HF (Hoes et al., 2010).
According to the current international and Dutch HF guidelines, GPs can use the plasma
concentration of brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide
(NT-proBNP) as an initial diagnostic test (Hoes et al., 2010; Yancy et al., 2013; Ponipowski et al.,
2016). Ponipowski et al. (2016) further recommend echocardiography to establish the diagnosis
in patients with suspected HF. In the Netherlands, the GP fulfills a role as gatekeeper, which
means that referrals to specialists are largely controlled by GPs. Until recently, Dutch GPs
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needed to refer patients with suspected HF to the cardiologist for
echocardiography. Nowadays, they can order it directly.
Insight in the occurrence of HF in relation to age and
comorbidity in routine general practice may improve the process
of diagnosing HF. Therefore, the aim of our study is to examine
the current prevalence of HF in relation to ageing, and the
occurrence of the main comorbidities in patients with HF,
separately for men and women as diagnosed by GPs in routine
daily practice. In addition, we want to describe the process of
diagnosing HF in routine primary care based on electronic
health record (EHR) data. Insight in the routine diagnostic
process may be helpful to improve care for this vulnerable group
of patients.
Methods
Design and study population
We conducted a retrospective cohort study, using data of patients of
eleven general practices participating in a Primary Care Practice
Based Research Network, the Nijmeegs Monitoring Project (NMP,
2011). GPs and practice nurses of these general practices record data
on care, disease and comorbidity. The data provided by the NMP
are first encoded and subsequently delivered to the Department of
Primary and Community Care in the Radboud University Medical
Center (Radboudumc) Nijmegen, the Netherlands. Patients of NMP
general practices are aware that their encoded data can be used in
research by the Radboudumc, and are given the opportunity to
object at any time (NMP, 2011).
Our study population consists of all adult patients (⩾18 years
of age) that were signed up at the general practice at some point
between 01/01/2010 and 31/12/2014. To answer our research
questions, we created two groups. The first group, called the
prevalence group (PG), consists of all patients that were present
on 31/12/2014 to estimate the point prevalence. The second
group, the diagnosis group (DG), consists of all adult patients
(including the PG group).
Heart failure, chronic comorbidities and clinical tests
HF is encoded using the International Classification of Primary
Care (ICPC) version 1 (ICPC1) or version 2 (ICPC2) com-
plemented with the International Classification of Diseases-10.
These ICPC codes are used to register morbidities as well as test
results during anamnesis (e.g., heart murmur). Patients were
defined as having HF when the ICPC code started with K77.
When HF was recorded more than once, we selected the first valid
date of diagnosis, since we considered HF a chronic disease. This
also applied to the included – chronic – comorbidities.
Demographic information included gender and age, which was
categorized (18–44/45–54/55–64/65–74/75–84/⩾ 85). Since HF
rarely occurs in patients younger than 44 years, the first category
was aggregated. The other categories were chosen to show the
(expected) correlation between higher age and the occurrence of
HF. In the PG, the mean age was calculated on 31/12/2014. In the
DG we included patients with and without HF, so it was not
possible to calculate the mean age at the time of diagnosis. The
mean age was therefore calculated on 01/01/2010.
The following chronic comorbidities were included: COPD,
DM, hypertension, anaemia and RFD (Hoes et al., 2010). The
ICPC codes used for these comorbidities are presented in Table 1.
For RFD we additionally included the laboratory test for renal
disease: estimated Glomerular Filtration Rate (eGFR). When
eGFR <60mL/min/1.73m2 was present, the patient was added as
a patient with RFD.
Routine practice of the diagnostic procedure in general prac-
tice was described according to the three pillars in the algorithm
from the HF guidelines: clinical symptoms in anamnesis, signs
during physical examination and additional clinical tests (Hoes
et al., 2010; Yancy et al., 2013; Ponipowski et al., 2016). This
information was available in ICPC codes, measurements and/or
free text (Table 1). We had no access to free text due to privacy
regulations (Krabben, 2005). The measurements were only
available from 2008 and onwards and comprised two elements:
(1) whether the measurements were recorded or not and (2) the
outcome of the measurement: suspected for HF or not. Of these,
we selected the first outcomes of the symptoms and signs that
were suspected for HF. This meant that an aberrant value over-
rode a normal value. This also applied to the outcomes of the
additional test results: an elevated value overrode a normal value.
The cut-off points used for BNP/NT-proBNP were 10 and
15 pmol/L, respectively (Hoes et al., 2010). ICPC codes and
measurements recorded in <15 patients were not included.
Statistical methods
The point prevalence in the PG was estimated on 31/12/2014. We
estimated this in men and women separately, and categorized by
age. In order to determine whether correction for clustering was
necessary, we calculated the intracluster correlation coefficient,
which was virtually zero (0,00000395). Therefore, we did not cor-
rect for clustering. The Wilson’s score interval was used to measure
the 95% confidence interval (95% CI). In the DG, we determined
the comorbidities in patients with and without HF and categorized
by gender and age. A χ 2 test was used to analyze differences in
comorbidities between patients with and without HF. A P-value
<0.05 was considered statistically significant. We also used the DG
to describe the process of diagnosing. As mentioned previously, all
ICPC codes assigned in the past were available, but measurements
were only available from 2008 and onwards. In addition, the cur-
rent Dutch guideline for HF is from 2010. For these reasons, we
composed two groups: no HF and HF diagnosed in 2010 or later.
Finally, we analyzed the symptoms, signs and additional clinical
tests for each group and the total group (including additionally HF
before 2010). First, we determined whether ICPC codes were pre-
sent or not and whether measurements were recorded or not.
Second, we determined if the outcomes were suspected for HF or
not in the HF group. Statistical Package for the Social Sciences
version 22 was used for statistical analysis. Characteristics of the PG
and the DG were provided using descriptive statistics.
Results
Point prevalence of heart failure
On 31/12/2014, 605 of the eligible patients in our PG (n= 49 362)
were diagnosed with HF. The overall point prevalence of HF in
the adult population was 1.3% (95% CI: 1.14–1.42) in men and
1.2% (95% CI: 1.06–1.33) in women (Table 2). The point pre-
valence in men and women increased with each age category,
starting with 0.04% (95% CI: 0.02–0.07) in patients younger than
44 years and increasing to 20.9% (95% CI: 17.96–24.08) in
patients aged 85 years or older. Until 54 years, men and women
showed comparable point prevalences. The point prevalence
in men aged 55–64 years was 1.0% (95% CI: 0.75–1.38) and in
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women 0.6% (95% CI: 0.37–0.84). Similar results were found in
patients aged 65–74 years: 2.9% (95% CI: 2.37–3.57) and 1.5%
(95% CI: 1.15–2.03), respectively. In patients aged 85 years or
older, the point prevalence was 21.8% (95% CI: 16.98–27.52) and
20.4% (95% CI: 16.87–24.36), respectively.
Comorbidities in heart failure patients
From the DG, three patients were excluded for whom no date of
diagnosis was known, leading to a total of 56 320 patients. Of this
group, 55 224 patients had no HF and 525 patients were diag-
nosed with HF in 2010 or later. COPD (24.1%), DM (34.7%),
hypertension (52.7%), anaemia (10.9%) and RFD (61.8%) were
highly common in patients with HF (Table 3). These comorbid-
ities were significantly lower in patients without HF (P< 0.001).
Similar results applied to both men and women (P< 0.001).
COPD was seen in 30.3% of men and in 18.0% of women with
HF. The opposite applied to hypertension, which was seen in
57.2% of women and 47.9% of men with HF, and RFD, which was
seen in 67.3% of women and 56.1% of men with HF. In addition,
Table 1. Overview of included variables in diagnosis group (Dutch College of General Practitioners 2016)
Measurement
code(s) Outcome
Coding
ICPC1 ICPC2 ICD10
Comorbidities
COPD – – R95 R95 –
DM – – T90.01
T90.02
T89
T90
E10
E11–
E14
Hypertension – – K85
K86
K87
K85
K86
K87
–
Anaemia – – B80 B80 –
RFD 1919 Normal (⩾60mL/min × 1.73m2)/reduced (<60mL/min × 1.73m2) U99.01 U99 N19
Symptoms
Dyspnoea 1659 Yes/no/unclear R02 R02 –
Orthopnoea 3010 Yes/no/unclear – – –
Fatigue 3256 Absent/present/unclear – – –
Anginal symptoms 1595 Yes/no/unclear – – –
Signs
Pulmonary crepitations 1868
2026
Normal/aberrant/unclear
Crepitations/rhonchi/extended expirium/eliminated breathing sounds/
remaining
– – –
Peripheral oedema 3007 Yes/no/unclear K07 K07 –
Elevated central venous
pressure
3000 Free text – – –
Enlarged liver 3005 Free text D96 D23 –
Ascites – D29.01 D29 R18
Widened ictus cordis 2062 Inside midclavicular line/outside midclavicular line/unclear – – –
Heart murmur 2060
2061
Normal/aberrant/unclear
Free text
K81 K81 –
Additional clinical tests
BNP 1966 Normal (<10 pmol/L)/elevated (⩾10 pmol/L) – – –
NT-proBNP 1968 Normal (<15 pmol/L)/elevated (⩾15 pmol/L) – – –
Chest X-ray 2321 Free text – – –
Electrocardiography 2202 Free text – – –
Echocardiography 3001 Free text – – –
ICPC= International Classification of Primary Care; ICD= International Classification of Diseases; COPD= chronic obstructive pulmonary disease; DM=diabetes mellitus; RFD= renal function
disorder; BNP=brain natriuretic peptide; NT-proBNP=N-terminal pro-BNP.
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statistical significance was calculated for each age category, which
is also shown in Table 3. The number of each comorbidity
increased with each age category, with a peak around 65–74 or
75–84 years, and decreased in patients aged 85 years or older.
Exceptions were RFD and anaemia, which had the highest
numbers in patients aged 85 years or older. Moreover, anaemia
was seen most in women aged 45–54 years without HF (4.4%)
and in women aged 55–64 years with HF (13.7%). Figure 1 shows
comorbidities in patients with and without HF per age category.
Process of diagnosing heart failure
Of all symptoms, the ICPC code for dyspnoea was recorded in
21.9% of patients with HF and in 3.4% of patients without HF
(Table 4). Anginal symptoms were recorded in 28.2 and 9.6%,
respectively. Of the signs, the ICPC code for peripheral oedema
was recorded in 27.2% of patients with HF and in 3.2% of patients
without HF. Of the additional tests, NT-proBNP was recorded in
38.1% of patients with HF and in 3.5% of patients without HF.
Anginal symptoms and auscultation of the lungs were suspected
for HF in 15.5 and 54.8% of the cases, respectively (not in Table).
NT-proBNP was elevated in 93.5% of the cases (not in Table).
Discussion
Prevalence, age and comorbidities
This retrospective cohort study showed an overall point pre-
valence of HF of 1.2% in the adult population. Prevalence
increased with each age category from 0.04% in patients younger
than 44 years to 20.9% in patients aged 85 years or older.
Comorbidities, COPD, DM, hypertension, anaemia and RFD,
were significantly more common in patients with HF than in
patients without HF. The symptoms and signs dyspnoea, anginal
symptoms and peripheral oedema were reported most frequently
in the process of diagnosing HF.
NT-proBNP
NT-proBNP was recorded in only 38.1% of HF patients, although
it is recommended in the HF guidelines as a test to assist GPs to
rule out HF. Especially in elderly patients with comorbidities,
such as COPD, HF patients may be overdiagnosed due to overlap
in symptoms and signs (Brenner et al., 2013). In these patients,
NT-proBNP would be useful to prevent overdiagnosing HF.
Comparison with existing literature
The prevalence rates found in our study are not comparable to
those presented in other studies, due to differences in region,
population (not primary care) and definitions/methods to assess
HF. Most studies estimated the prevalence of HF by conducting a
population-based study in which patients underwent diagnostic
work-up and sometimes an expert panel was used to make the
final diagnosis. Moreover, these studies only included patients
older than 45–55 years, which led to higher overall prevalence
rates (Mosterd et al., 1999; Daamen et al., 2015). However,
Engelfriet et al. (2012) and Van Baal et al. (2010) did conduct a
comparable study to estimate the prevalence rates of HF in the
Netherlands. They found comparable overall prevalence rates, but
lower rates (between 11 and 16%), in patients aged 85 years or
older. These differences can possibly be explained by the ageing of
the population in the Netherlands. Our findings regarding the
high number of comorbidities in HF patients were consistent with
other studies (Van Deursen et al., 2014). Although common risk
factors are likely to contribute, HF itself might cause other
comorbidities, and treatment of HF may have a negative impact,
for example on renal function. Consequently, HF, often compli-
cated by comorbidities, has started to put a great burden on the
GP in recent years, which can be expected to increase even more.
In our study, the selected variables to represent symptoms,
signs and additional tests were barely recorded. It is plausible to
assume that these variables are not recorded in the way they were
extracted because GPs use free text in patients’ medical files to
describe data instead of coding them. A study of Vijayakrishnan
et al. (2014), performed in the USA, used data extracted from free
text and showed much higher percentages for documented
symptoms and signs in primary care. As mentioned before, we
had no access to free text in the EHR in our database which is in
accordance with the guidelines of the Dutch data protection
authorities (Krabben, 2005). In addition, diagnostic tests per-
formed in secondary care, are not included in the primary care
EHR. Confirmation by echocardiography is mandatory to diag-
nose HF (Hoes et al., 2010; Yancy et al., 2013; Ponipowski et al.,
2016). Valk et al. (2016) performed a study in which turned out
that more than one-third of patients labelled with HF in primary
care might not have HF. In this study, in case patients labelled
with HF had not yet undergone echocardiography, their GP
was recommended to refer for an echocardiography to confirm
the diagnosis. This shows the importance of echocardiography in
the process of diagnosing HF. Unfortunately no data of
Table 2. Prevalence (%) of heart failure in the adult population (prevalence group)
Men Women Total
Age (years) n Prevalence % (95% CI) n Prevalence % (95% CI) n Prevalence % (95% CI)
18–44 4 0.04 (0.01–0.10) 4 0.04 (0.01–0.09) 8 0.04 (0.02–0.07)
45–54 18 0.4 (0.23–0.57) 16 0.3 (0.20–0.53) 34 0.3 (0.25–0.48)
55–64 41 1.0 (0.75–1.38) 23 0.6 (0.37–0.84) 64 0.8 (0.62–1.00)
65–74 88 2.9 (2.37–3.57) 46 1.5 (1.15–2.03) 134 2.2 (1.88–2.62)
75–84 108 8.2 (6.69–9.85) 116 7.9 (6.59–9.34) 224 8.0 (7.08–9.10)
⩾ 85 51 21.8 (16.98–27.52) 90 20.4 (16.87–24.36) 141 20.9 (17.96–24.08)
Total 310 1.3 (1.14–1.42) 295 1.2 (1.06–1.33) 605 1.2 (1.13–1.33)
CI= confidence interval.
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Table 3. Comorbidities in patients with and without heart failure (HF)
Men (n= 27 556) Women (n= 28 764) Total (n= 56 320)
No HF (n= 27 019) HF (n= 537) No HF (n= 28 205) HF (n= 559) No HF (n= 55 224) HF (n= 1096)
n % n % P-value n % n % P-value n % n % P-value
COPD 937 3.5 163 30.3 < 0.001 801 2.8 101 18.0 < 0.001 1738 3.1 264 24.1 < 0.001
18–44 64 0.5 0 0.0 > 0.99 55 0.4 0 0.0 > 0.99 119 0.4 0 0.0 > 0.99
45–54 145 2.9 4 12.9 0.012 172 3.3 0 0.0 > 0.99 317 3.1 4 7.8 0.074
55–64 260 6.1 24 29.6 < 0.001 277 6.6 13 25.5 < 0.001 537 6.3 37 28.0 < 0.001
65–74 286 11.6 44 29.5 < 0.001 175 6.9 29 28.4 < 0.001 461 9.2 73 29.1 < 0.001
75–84 162 16.8 72 35.8 < 0.001 98 8.2 37 17.5 < 0.001 260 12.0 109 26.4 < 0.001
⩾ 85 20 12.0 19 28.8 0.002 24 6.9 22 13.3 0.018 44 8.6 41 17.7 < 0.001
DM 1920 7.1 181 33.6 < 0.001 1660 5.9 199 35.5 < 0.001 3580 6.5 380 34.7 < 0.001
18–44 200 1.4 2 22.2 0.007 192 1.3 1 11.1 0.11 392 1.4 3 16.7 0.002
45–54 341 6.8 11 35.5 < 0.001 236 4.5 2 10.0 0.23 577 5.6 13 25.5 < 0.001
55–64 601 14.0 24 29.6 < 0.001 414 9.8 19 37.3 < 0.001 1015 11.9 43 32.6 < 0.001
65–74 505 20.5 58 38.9 < 0.001 470 18.6 40 39.2 < 0.001 975 19.5 98 39.0 < 0.001
75–84 234 24.2 72 35.8 0.001 273 22.8 92 43.4 < 0.001 507 23.5 164 39.7 < 0.001
⩾ 85 39 23.5 14 21.2 0.71 75 21.7 45 27.3 0.16 114 22.3 59 25.5 0.33
Hypertension 4022 14.9 257 47.9 < 0.001 4822 17.1 321 57.2 < 0.001 8844 16.0 578 52.7 < 0.001
18–44 362 2.6 2 22.2 0.21 491 3.3 3 33.3 0.003 853 3.0 5 27.8 < 0.001
45–54 745 14.8 11 35.5 0.004 848 16.3 7 35.0 0.033 1593 15.5 18 35.3 < 0.001
55–64 1305 30.4 41 50.6 < 0.001 1294 30.6 21 41.2 0.073 2599 30.5 62 47.0 < 0.001
65–74 1053 42.8 69 46.3 0.39 1241 49.0 55 53.9 0.33 2294 45.9 124 49.4 0.28
75–84 487 50.5 105 52.2 0.65 739 61.8 136 64.2 0.51 1226 56.7 241 58.4 0.54
⩾ 85 70 42.2 29 43.9 0.81 209 60.4 99 60.0 0.93 279 54.5 128 55.4 0.82
Anaemia 241 0.9 56 10.4 < 0.001 1024 3.6 63 11.2 < 0.001 1265 2.3 119 10.9 < 0.001
18–44 27 0.2 0 0.0 > 0.99 534 3.6 0 0.0 > 0.99 561 1.9 0 0.0 > 0.99
45–54 41 0.8 2 6.5 0.028 231 4.4 2 10.0 0.22 272 2.7 4 7.8 0.047
55–64 44 1.0 7 8.6 < 0.001 108 2.6 7 13.7 < 0.001 152 1.8 14 10.6 < 0.001
65–74 74 3.0 16 10.7 < 0.001 71 2.8 10 9.8 0.001 145 2.9 26 10.4 < 0.001
75–84 42 4.4 21 10.4 0.001 62 5.2 20 9.4 0.15 104 4.8 41 9.9 < 0.001
⩾ 85 13 7.8 10 15.2 0.09 18 5.2 24 14.5 < 0.001 31 6.1 34 14.7 < 0.001
RFD 1704 6.3 301 56.1 < 0.001 2464 8.7 376 67.3 < 0.001 4168 7.5 677 61.8 < 0.001
18–44 92 0.7 2 22.2 0.002 113 0.8 2 22.2 0.002 205 0.7 4 22.2 < 0.001
45–54 150 3.0 7 22.6 < 0.001 277 5.3 5 25.0 0.003 427 4.2 12 23.5 < 0.001
55–64 416 9.7 35 43.2 < 0.001 596 14.1 25 49.0 < 0.001 1012 11.9 60 45.5 < 0.001
65–74 565 22.9 71 47.7 < 0.001 724 28.6 64 62.7 < 0.001 1289 25.8 135 53.8 < 0.001
75–84 398 41.2 134 66.7 < 0.001 576 48.2 153 72.2 < 0.001 974 45.1 287 69.5 < 0.001
⩾ 85 83 50.0 52 78.8 < 0.001 178 51.4 127 77.0 < 0.001 261 51.0 179 77.5 <0.001
COPD= chronic obstructive pulmonary disease; DM=diabetes mellitus; RFD= renal function disorder. Bold P-values are statistically significant.
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echocardiography were available in our study, because this is
recorded in free text.
Strengths and limitations
Some limitations of our study should be considered. First, we
made no distinction between acute and chronic HF, therefore we
used the lowest cut-off point of NT-proBNP. This did not alter
our findings since, according to the guidelines, the diagnosis of
acute HF is primarily based on anamnesis and physical
examination (Hoes et al., 2010; Yancy et al., 2013; Ponipowski
et al., 2016), and we already included these in our study. Another
limitation is that we might have missed recordings of diagnostic
tests for HF since these tests could be performed in secondary
care. It is estimated that about 50% of patients with HF are
referred to a cardiologist (RIVM, 2018). Furthermore, we could
not use free text to study symptoms, signs and additional clinical
tests and therefore we could not study echocardiographic
assessment unfortunately. Besides, recall or recording bias might
have arisen in this study concerning the numbers for dyspnoea,
Figure 1. Bar graph of comorbidities in patients with and without heart failure per age category
HF=heart failure; COPD= chronic obstructive pulmonary disease
Table 4. Recorded symptoms, signs and additional tests in patients with and without heart failure (HF)
No HF HF diagnosed in 2010 or later Total (diagnosis group)a
n= 55 224 98.1% n= 525 0.9% n= 56 320 100%
Symptoms
Dyspnoea ICPC 1870 3.4 115 21.9 2071 3.7
Dyspnoea anamnesis 423 0.8 11 2.1 444 0.8
Anginal symptoms 5294 9.6 148 28.2 5576 9.9
Signs
Auscultation lungs 1166 2.1 31 5.9 1227 2.2
Abnormalities auscultation lungs 179 0.3 17 3.2 206 0.4
Peripheral oedema ICPC 1782 3.2 143 27.2 2034 3.6
Peripheral oedema physical examination 56 0.1 2 0.4 58 0.1
Auscultation heart 363 0.7 8 1.5 381 0.7
Abnormalities auscultation heart 23 0.04 1 0.2 25 0.04
Heart murmur ICPC 363 0.7 6 1.1 372 0.7
Additional tests
BNP 6 0.01 0 0.0 16 0.03
NT-proBNP 1934 3.5 200 38.1 2365 4.2
ICPC= International Classification of Primary Care; BNP=brain natriuretic peptide; NT-proBNP=N-terminal pro-BNP.
Not/seldom recorded: symptoms: orthopnoea, fatigue, signs: elevated central venous pressure, enlarged liver, ascites, widened ictus cordis, additional tests: echocardiography, electro-
cardiography, chest X-ray.
aThis group included no HF (n= 55 224), HF diagnosed in 2010 or later (n= 525) and HF before 2010 (n= 571).
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anginal symptoms and peripheral oedema. However, this does not
apply to BNP and NT-proBNP as all laboratory values that are
ordered by the GP are added automatically to the EHR. Finally,
our conclusions regarding the relation between HF and comor-
bidities are not based on specific age categories. However, when
looking at HF and comorbidities within the different age cate-
gories, the majority remains statistically significant. For example,
RFD shows statistical significance in every age category.
A strength of our study is that it describes routine care for HF
patients in general practice, where most HF patients are diag-
nosed and managed. Furthermore, we used data from general
practices which are affiliated with the Radboudumc and have
been shown to have very accurate ways of registration (Van der
Wel et al., 2008). Another strength of our study is that we believe
our study population to be representative for the overall popu-
lation and therefore, our study results to be generalizable to
patients with and without HF in the general adult population.
Implications for practice
HF is highly associated with ageing and comorbidities, which
makes the process of diagnosing HF in our ageing population
more challenging. The complexity of this syndrome requires more
comorbidity-specific recommendations in the existing guidelines,
especially for the combination of HF and COPD or RFD. Our
results show that symptoms and signs of HF were infrequently
recorded and that additional tests were requested in 38% of the
patients. This is partly explained by the fact that the diagnostic
process may have been performed in secondary care, which was
not included in our database. Also, these findings reflect a com-
bination of the recording discipline of the GPs and the actual
performance on diagnostic procedures. Despite these caveats, our
study indicates that the process of diagnosing HF shows room for
improvement. In particular, diagnostic use of NT-proBNP in
routine primary care seems underutilized. Preliminary qualitative
analysis among GPs from our research institute, suggests that
(lack of) knowledge of the HF guidelines determines the (lack of)
of measurement of NT-proBNP. Instruction of GPs to determine
NT-proBNP in patients suspected of HF is recommended, espe-
cially in elderly patients with comorbidities.
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